Antiviral efficacy

Last updated: 2022 Jul 13
Total hit(s): 116
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
12.5µg of Oridonin had zero relative copies of viral RNA in the supernatant of VeroE6 cells, 48hrs post-infection. Oridonin had an inhibitory EC50 of 4.95µm. Catalytic activity of 3CLpro in vitro was inhibited by Oridonin at an IC 50 of 2.16µm. Oridonin is a novel candidate to develop a new antiviral treatment for COVID-19.
✍
 		35600064
()
PMID
35600064
Title Oridonin Inhibits SARS-CoV-2 by Targeting Its 3C-Like Protease
Impact factor
N/A
Date of Entry 2022 Jul 13

Eleven naturally occuring polyether ionophores and one synthetic analog were screened and found that all of them display inhibitory activity but X-206 showed high selectivity of 584-fold, and could inhibit viral replication at EC50 = 14 nM. Some polythereionophores accumulate in lysosomes and inhibits autophagy and alters pH because of exchange of metal cations for protons which may underlie antiviral activity.
✍
 		33248195
(Antiviral Res)
PMID
33248195
Date of Publishing: 2021 Jan
Title Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro
Author(s) nameSvenningsen EB, Thyrsted J et al.
Journal Antiviral Res
Impact factor
4.12
Citation count: 2
Date of Entry 2022 Jan 17

VeroE6 cells infected with SARS-CoV-2 WT (B.1.1.70) or VOC B.1.1.7 (alpha) and B.1.351 (beta) strains, on treatment with budesonide or Pulmicort showed reduced viral titers at IC50 ranging between 4.8 and 20 µ;M. Cytotoxicity assay revealed no effect on the cell viability.
✍
 		34372616
(Viruses)
PMID
34372616
Date of Publishing: 2021 Jul 20
Title Antiviral Effect of Budesonide against SARS-CoV-2
Author(s) nameHeinen N, Meister TL et al.
Journal Viruses
Impact factor
3.76
Citation count: 4
Date of Entry 2021 Nov 23

SID 26681509 significantly inhibits SARS-CoV-2 pseudovirus infection in Huh7 cells. SID 26681509 exhibits cytotoxicity, hence not used for further experiments.
✍
 		33774649
(Signal Transduct Target Ther)
PMID
33774649
Date of Publishing: 2021 Mar 27
Title Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Author(s) nameZhao MM, Yang WL et al.
Journal Signal Transduct Target Ther
Impact factor
- n/a -
Citation count: 73
Date of Entry 2021 Aug 23

Amantadine inhibits SARS-CoV-2 pseudovirus infection in Huh7 cells by reducing the Cathepsin L (CTSL) enzyme activity. Amantadine can be used as a therapeutic.
✍
 		33774649
(Signal Transduct Target Ther)
PMID
33774649
Date of Publishing: 2021 Mar 27
Title Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Author(s) nameZhao MM, Yang WL et al.
Journal Signal Transduct Target Ther
Impact factor
- n/a -
Citation count: 73
Date of Entry 2021 Aug 23

E64d inhibits SARS-CoV-2 pseudovirus infection in Huh7 cells by reducing the Cathepsin L (CTSL) enzyme activity. E64d can be used as a therapeutic as it inhibits CTSL enzyme activity.
✍
 		33774649
(Signal Transduct Target Ther)
PMID
33774649
Date of Publishing: 2021 Mar 27
Title Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Author(s) nameZhao MM, Yang WL et al.
Journal Signal Transduct Target Ther
Impact factor
- n/a -
Citation count: 73
Date of Entry 2021 Aug 23

Antiviral efficacy of Astemizole which inhibits the entry of SARS-CoV-2 Spike pseudoviruses into ACE2-expressed HEK293T cells by binding to the ACE2 receptor. SARS-COV-2 Spike pseudotype virus to enter the ACE2 cells were reduced significantly.
✍
 		33932547
(Microb Pathog)
PMID
33932547
Date of Publishing: 2021 Apr 28
Title Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro
Author(s) nameWang X, Lu J et al.
Journal Microb Pathog
Impact factor
2.64
Citation count: 2
Date of Entry 2021 Aug 10

Type I PRMT inhibitor (MS023) inhibits interaction of N protein with the 5-UTR of SARS-CoV-2 genomic RNA, a property required for viral packaging. PRMT inhibitors, cancer drug canditates, have found to methylate arginine in the N protein, thereby regulating the SARS-CoV-2 lifecycle.
✍
 		34029587
(J Biol Chem)
PMID
34029587
Date of Publishing: 2021 May 23
Title Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replication
Author(s) nameCai T, Yu Z et al.
Journal J Biol Chem
Impact factor
3.96
Citation count: 11
Date of Entry 2021 Jul 28

Anti-viral activity of six drugs (arbidol, baloxavir, laninamivir, oseltamivir, peramivir, and zanamivir) against SARS-Co-V-2 was tested and among them only arbidol compound demonstrated to efficiently inhibit the virus infection in vitro. Further clinical studies on Arbidol should be done to check its efficacy and validate the recommended dosage to treat COVID-19 patients.
✍
 		32373347
(Cell Discov)
PMID
32373347
Date of Publishing: 2020
Title The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
Author(s) nameWang X, Cao R et al.
Journal Cell Discov
Impact factor
4.65
Citation count: 122
Date of Entry 2021 Jun 15

In vitro activity of three Abl tyrosine kinase inhibitors- nilotinib, imatinib and dasatinib against SARS-CoV-2 was analysed in Vero-E6 and Calu-3 cells. The combinational therapy using antiviral and anti-inflammatory drugs is found to be one of the effective strategy to combat SARS-CoV-2.
✍
 		33232578
(Basic Clin Pharmacol Toxicol)
PMID
33232578
Date of Publishing: 2020 Nov 24
Title The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro
Author(s) nameCagno V, Magliocco G et al.
Journal Basic Clin Pharmacol Toxicol
Impact factor
2.29
Citation count: 14

Invitro studies of chlorpheniramine shows strong virucidal effect against SARS-CoV-2 infected Vero cell line. CPM's antivirial and anti-inflammatory effects , with minimal side effects could be used in the early treatment and prevention of viral infections like influenzaA/B and COVID-19.
✍
 		32963923
(Cureus)
PMID
32963923
Date of Publishing: 2020 Sep 17
Title In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2
Author(s) nameWestover JB, Ferrer G et al.
Journal Cureus
Impact factor
- n/a -
Citation count: 9

Ciclesonide showed increased IC50 (by >2 fold change) in Calu-3 cells compared to Vero cells. Ciclesonide showed IC50 of 4.33 micromolar in Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Berbamine hydrochloride showed increased IC50 (by >4 fold change) in Calu-3 cells compared to Vero cells. Berbamine hydrochloride IC50 of 7.87 micromolar in Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Amodiaquine dihydrochloride showed increased IC50 (by >4 fold change) in Calu-3 cells compared to Vero cells. Amodiaquine dihydrochloride IC50 of 5.15 micromolar in Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Salinomycin sodium showed increased IC50 (by >2 fold change) in Calu-3 cells compared to Vero cells. Salinomycin sodium IC50 of 0.24 micromolar in Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Mefloquine showed increased IC50 (by >4 fold change) in Calu-3 cells compared to Vero cells. Mefloquine showed IC50 of 4.33 micromolar in Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Lopinavir showed increased IC50 (by >2 fold change) in Calu-3 cells compared to Vero cells. Lopinavir showed IC50 of 9.12 micromolar in Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Digitoxin showed decreased IC50 (by <1 fold change) in Calu-3 cells compared to Vero cells. Digitoxin showed IC50 of 0.23 micromolar de Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Cyclosporine showed decreased IC50 (by <1 fold change) in Calu-3 cells compared to Vero cells. Cyclosporine showed IC50 of 5.82 micromolar de Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Ouabain showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells. Ouabain showed IC50 of 0.1 micromolar un Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Eltrombopag showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells. Eltrombopag showed IC50 of 8.27 micromolar un Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Loperamide hydrochloride showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells. Loperamide hydrochloride IC50 of 9.27 micromolar un Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Hexachlorophene showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells. Hexachlorophene showed IC50 of 0.9 micromolar un Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Ivacaftor showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells. Ivacaftor showed IC50 of 6.57 micromolar un Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40

Oxyclozanide showed unchanged IC50 (fold change approximately 1) in Calu-3 cells compared to Vero cells. Oxyclozanide showed IC50 of 3.71 micromolar un Vero cells
✍
 		32767684
(J Med Virol)
PMID
32767684
Date of Publishing: 2020 Aug 7
Title Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells
Author(s) nameKo M, Jeon S et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 40